Skip to content

Randomized, single-blind, parallel-controlled, multicenter clinical trial for evaluation of the efficacy and safety of biohernia patches in the treatment of inguinal hernia

Randomized, single-blind, parallel-controlled, multicenter clinical trial for evaluation of the efficacy and safety of biohernia patches in the treatment of inguinal hernia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020173
Enrollment
Unknown
Registered
2018-12-19
Start date
2018-12-01
Completion date
Unknown
Last updated
2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal hernia

Interventions

Test group of open surgery queue:The standard tension-free herniorrhaphy (Lichtenstei) procedure was performed using the zhuoruan biological herniorrhaphy mesh
Control group of open surgery queue:COOK's baide plug herniorrhaphy mesh was used to perform standard tension-free herniorrhaphy (Lichtenstei)
Test group of laparoscopic surgery queue:Laparoscopic hernia repair using Zhuoruan biological hernia patch
Control group of laparoscopic surgery queue:Laparoscopic hernia repair using Ultrapro mesh

Sponsors

Huadong Hospital?Ruijin Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 85 years male or female; 2. Unilateral primary inguinal hernia while open surgery for Gilbert parting I~ V and laparoscopic surgery in Gilbert points I~ VII; 3. Herniorrhaphy is required without absolute contraindications; 4. Patients voluntarily participate in clinical trials and sign informed consent forms, which can cooperate with clinical follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with bilateral inguinal hernia, incarcerated hernia/strangulated hernia, recurrent hernia or intestinal obstruction; 2. Unable to accept pig-derived equipment due to religious or ethnic issues; 3. Participated in clinical trials of other drugs or medical devices in the last 6 months; 4. Patients with acute infection or those with poor control of focal infection have skin diseases around the incision; 5. Severe heart, liver and kidney insufficiency is defined as: (1) cardiac function: level III and above; (2) 2.5 times the normal upper limit of ALT or AST; (3) 2.5 times the normal upper limit of serum creatinine. 6. The presence of serious diseases (such as severe prostatic hyperplasia, constipation, asthma or chronic cough) causing increased abdominal pressure; Uncontrollable ascites caused by cirrhosis of the liver or tumor, etc.); 7. Poor control of diabetic patients (fasting blood glucose > 11.1mmol/L); 8. Patients with various malignant tumors and chronic wasting diseases that cause dysplasm and cannot tolerate surgery; Life expectancy less than 6 months; 10. Specific allergy constitution; 11. Obvious abnormal coagulation function (prothrombin time extended > for 6 seconds); 12. Pregnant or planned pregnant women and lactating women; 13. Mentally abnormal without the ability to act autonomously; 14. Other circumstances in which doctors judge that they cannot participate in the test.

Design outcomes

Primary

MeasureTime frame
None-recurrence rate of hernia 180 days after operation;

Countries

China

Contacts

Public ContactYanyan Wang

Zhuo Ruan Medical Technology (Suzhou) Co., Ltd.

wyy@exmed.cn+86 13916805372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026